skinny.

Latest / The HemOnc Pulse

Redirected Strategy: Tal and TEC in the Myeloma Mix

In this episode of The HemOnc Pulse, Rahul Banerjee, MD of Fred Hutchinson Cancer Center is joined by Gurbakhash Kaur, MD of Mount Sinai for an in-depth discussion of the RedirecTT-1 trial, recently published in the New England Journal of Medicine. The conversation explores the evolving role of bispecific antibodies in multiple myeloma, with a focus on the combination of talquetamab (Tal) and teclistamab (TEC). Drs. Banerjee and Kaur unpack the trial’s rationale, design, and real-world implications for patients with relapsed or refractory disease.

Tune in to hear expert perspectives on unmet…

Log in to save or queue this episode.

The skinny

The skinny isn't ready yet — notes appear once the transcript is processed.